Published in Medical Letter on the CDC and FDA, October 3rd, 2004
The indication has been granted fast track status by the FDA, a designation designed to facilitate the development and expedite the review of drugs that address serious, unmet medical needs.
Pegasys is approved for use alone and in combination with Copegus for the treatment of chronic hepatitis C. Pegasys and Copegus are the first hepatitis C medications...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.